AI could revolutionize liver cancer treatment by predicting who will benefit most
NCT ID NCT07584317
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether an artificial intelligence (AI) model can predict how well liver cancer patients will respond to a combination of treatments, including a procedure called TACE, immunotherapy, and targeted therapy. Researchers will analyze medical images and other data from 1,170 participants to see if the AI can accurately forecast outcomes. The goal is to personalize treatment decisions and improve results for people with hepatocellular carcinoma.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Could a vaccine help fight Hard-to-Treat cancers?
- Could a tailored diet before surgery boost liver cancer recovery?
- Can a new PET tracer light up hidden cancers?
- A new test could reveal how radiation affects the liver
- Can an immunotherapy drug keep liver cancer at bay after surgery?